Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH0ROP)

• Drug Name: Maltose Drug Info
• Synonyms: beta-maltose; Maltobiose; Maltose, pure; Advanctose 100; 4-O-alpha-D-glucopyranosyl-beta-D-glucopyranose; Cextromaltose; Maltodiose; Finetose; Sunmalt; Malt sugar; Finetose F; Sunmalt S; UNII-R4B6462NGR; D-Glucose, 4-O-alpha-D-glucopyranosyl-; AI3-09089; EINECS 200-716-5; BRN 0093798; 4-O-alpha-D-Glucopyranosyl-D-glucose; R4B6462NGR; 4-(alpha-D-Glucosido)-D-glucose; CHEBI:18147; beta-D-Cellobiose; GUBGYTABKSRVRQ-QUYVBRFLSA-N; beta-D-glucopyranose, 4-O-alpha-D-glucopyranosyl-
• Cross-matching ID:
  PubChem CID: 6255
  ChEBI ID: CHEBI:18147
  CAS Number: CAS 133-99-3
  TTD Drug ID: DMH0ROP
  INTEDE Drug ID: DR2110

Molecule-Related Drug Atlas

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[8]
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[9]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[10]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[11]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[12]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[13]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[13]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[13]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[14]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[14]

Drug(s) Targeting Intestinal maltase-glucoamylase (MGAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voglibose	DMUBP9O	Diabetic complication	5A2Y	Approved	[15]
Acarbose	DMRM3AW	Diabetic complication	5A2Y	Approved	[16]
Miglitol	DMXBQAM	Diabetic complication	5A2Y	Approved	[17]
Rh-alphaglucosidase	DMNF0G8	Pompe disease	5C51.3	Approved	[18]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[10]
Alpha-glucosidase	DM2RTGP	Muscle disease	FB3Z	Phase 3	[19]
PAZ-320	DMU0812	Type-2 diabetes	5A11	Phase 2	[20]
SC-49483	DM180VX	Acquired immune deficiency syndrome	1C62.3	Phase 2	[21]
SALACINOL	DMVKQT8	N. A.	N. A.	Phase 1/2	[22]
Celgosivir	DMD1V7I	Dengue fever	1D2Z	Phase 1/2	[23]

Drug(s) Metabolized By Cellobiose 2-epimerase (CE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[4]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[4]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[4]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[4]
Lactose	DMO4GPK	Discovery agent	N.A.	Phase 1	[4]

Drug(s) Metabolized By Fructokinase (scrK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sucrose	DMVWUCF	Discovery agent	N.A.	Investigative	[5]

Drug(s) Metabolized By Alpha-glucosidase (aglA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Isomaltose	DMD1KSW	N. A.	N. A.	Investigative	[7]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Inhibitor	[1]
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Inhibitor	[1]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Sucrase-isomaltase intestinal (SI)	DE5EO4Y	SUIS_HUMAN	Substrate	[2]
Maltose phosphorylase (malP)	DE7NXHG	Q5FI04_LACAC	Substrate	[3]
Cellobiose 2-epimerase (CE)	DERDXAF	CEEP_RUMAL	Substrate	[4]
Fructokinase (scrK)	DEBW1FU	SCRK_FUSMR	Substrate	[5] , [6]
Cellobiose 2-epimerase (CE)	DEGLW18	A0A173SS24_9FIRM	Substrate	[4]
Cellobiose 2-epimerase (CE)	DENTGJO	A0A173Z970_9FIRM	Substrate	[4]
Cellobiose 2-epimerase (CE)	DE4XLDR	A0A174ZCD1_9FIRM	Substrate	[4]
Cellobiose 2-epimerase (CE)	DEGBVKJ	A9KK53_LACP7	Substrate	[4]
Cellobiose 2-epimerase (CE)	DEDY9F6	CEEP_EUBCE	Substrate	[4]
Alpha-glucosidase (aglA)	DEST6E5	A0A173ZA10_9FIRM	Substrate	[7]

References

• [1] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [2] Structural basis for substrate selectivity in human maltase-glucoamylase and sucrase-isomaltase N-terminal domains. J Biol Chem. 2010 Jun 4;285(23):17763-70.
• [3] Rational engineering of Lactobacillus acidophilus NCFM maltose phosphorylase into either trehalose or kojibiose dual specificity phosphorylase. Protein Eng Des Sel. 2010 Oct;23(10):781-7.
• [4] Cloning and sequencing of the gene for cellobiose 2-epimerase from a ruminal strain of Eubacterium cellulosolvens. FEMS Microbiol Lett. 2008 Oct;287(1):34-40.
• [5] Sugar metabolism by fusobacteria: regulation of transport, phosphorylation, and polymer formation by Fusobacterium mortiferum ATCC 25557. Infect Immun. 1991 Dec;59(12):4547-54.
• [6] Clinical Fusobacterium mortiferum isolates cluster with undifferentiated Clostridium rectum species based on 16S rRNA gene phylogenetic analysis. Ann Clin Lab Sci. 2016 May;46(3):279-81.
• [7] Novel alpha-glucosidase from human gut microbiome: substrate specificities and their switch. FASEB J. 2010 Oct;24(10):3939-49.
• [8] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [9] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
• [10] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [11] Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
• [12] ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
• [13] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [14] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [15] Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
• [18] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [19] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
• [20] Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
• [21] Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
• [22] Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.
• [23] Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection.Curr Opin Investig Drugs.2009 Aug;10(8):860-70.